Ingredient or product comparison
Comparison Table: Baseline vs Post-Treatment Lab Expectations
hsCRP 0.5–5.0 mg/L 20–40% reduction if baseline >2.0 mg/L Reduction = systemic anti-inflammatory effect confirmed Increase dose 20–30%, rule out concurrent inflammation sources Ceruloplasmin 20–60 mg/dL Stable or +10–15% if baseline <25 mg/dL Elevation = coppe
This source-based comparison does not add ratings or recommend a winner.
- hsCRP
- 0.5–5.0 mg/L
- 20–40% reduction if baseline >2.0 mg/L
- Reduction = systemic anti-inflammatory effect confirmed
- Increase dose 20–30%, rule out concurrent inflammation sources
- Ceruloplasmin
- 20–60 mg/dL
- Stable or +10–15% if baseline <25 mg/dL
- Elevation = copper delivery to tissues, suppression = possible overload
- Add zinc if ceruloplasmin >70 mg/dL, check serum copper
- Serum Copper
- 70–140 µg/dL
- 90–120 µg/dL (mid-range optimal)
- Mid-range = homeostasis maintained
- Reduce dose if >140 µg/dL, increase if <80 µg/dL
- Zinc
- 60–120 µg/dL
- Stable, copper-to-zinc ratio 0.7–1.0
- Stable ratio = balanced mineral status
- Supplement zinc if ratio >1.2
- IGF-1
- Age-adjusted norms
- Stable or +10–20%
- Modest increase = enhanced tissue responsiveness
- Evaluate other peptides or training if >50% increase